© Reuters. FILE PHOTO: The offices of gene sequencing company Illumina Inc are shown in San Diego, California January 11, 2016. REUTERS/Mike Blake
BRUSSELS (Reuters) – EU antitrust regulators opened on Thursday a full-scale investigation into U.S. life sciences company Illumina Inc (NASDAQ:)’s proposed buy of cancer test maker Grail Inc, worried that the deal may curb innovation and competition.
The European Commission’s announcement confirmed a Reuters story last week.
“The proposed acquisition may reduce competition and innovation in the emerging market for the development and commercialisation of cancer detection tests based on sequencing technologies,” the EU executive, which acts as the competition enforcer for the 27-country bloc, said.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.